Claire Bugos

1 week ago | verywellhealth.com | Claire Bugos

People using GLP-1 drugs to manage their weight may be more likely to develop acne, according to a recent report. In a retrospective study, researchers analyzed the number of acne vulgaris diagnoses among people with obesity but not diabetes who had been prescribed Saxenda (liraglutide), Wegovy (semaglutide), or Zepbound (tirzepatide). The researchers matched more than 162,000 GLP-1 drug users—three-quarters of whom were women—with people who were not taking the medications.

2 weeks ago | verywellhealth.com | Claire Bugos |Nick Blackmer

As women age, their bodies transform. Fat more easily settles in their midsection. They tend to process calories slower and exercise less. Some of these changes happen as a natural part of aging, while others are related to shifts in sex hormones during the menopausal transition. Bodily changes during the menopause transition increase the risk of metabolic conditions such as obesity and diabetes.

4 weeks ago | verywellhealth.com | Claire Bugos

Genetic testing company 23andMe filed for bankruptcy in the United States on Sunday, raising concerns about the fate of highly sensitive genetic data from its 15 million customers. The company, best known for its at-home DNA testing kits, said it would continue to operate and would not change the way it protects consumer data while in bankruptcy court. Co-founder Anne Wojcicki stepped down as CEO this week and will attempt to buy the company back.

1 month ago | verywellhealth.com | Claire Bugos

Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price for people who are uninsured or insured on commercial plans that don't cover the obesity drug. Through the NovoCare program, patients can purchase a month’s supply of Wegovy for $499. All dose strengths, from 0.25 milligrams to 2.4 milligrams, are priced the same. The list price for Wegovy is around $1,350 per month.

1 month ago | verywellhealth.com | Claire Bugos

Researchers suspect that environmental factors may play a role in the rise of colorectal cancer rates in younger adults. Microplastics can disrupt the gut lining, potentially allowing harmful toxins and bacteria to enter and contribute to cancer development. Scientists are investigating how microplastics may cause imbalances in the gut microbiome. Young adults today are relatively healthy—they generally drink less, exercise more, and eat healthier than older adults.